GE shares are hopping again when Wall Street loves Danaher deal

UBS analyst Peter Lennox-King believes this new source of money for GE, as well as the benefits, is a blessing to the company.

"The sale of GE BioPharma to Danaher effectively puts the issue at bay," Lennox-King said.

Nicole DeBlase, analyst from Deutsche Bank, was anyway among the groups, but despite raising the firm's price target for GE to $ 11 per share.

"GE is left with the less attractive parts of the Healthcare business," said DeBlase of the deal.

Here's what great Wall Street analysts said about GE's deal.

Source link

Back to top button